Recordati Group
Clinical trials sponsored by Recordati Group, explained in plain language.
Recordati Group
REC
BORSA ITALIANA
Pharmaceutical company focused on rare diseases and specialty treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cushing's drug osilodrostat under Long-Term safety review Results expected Jun 2027 (estimated)
- New hope for kids with Cushing's: drug trial launches Results expected Jul 2027 (estimated)